Objective
The Fund’s investment objective is to generate returns that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index (the “Index”). The Fund is passively managed. The Fund will aim to achieve its investment objective by attempting to replicate the performance of the Index by investing primarily in a portfolio of equity securities that as far as possible and practicable consists of the component securities of the Index in similar proportions to their weightings in the Index and in american depositary receipts (“ADRs”) and global depositary receipts (“GDRs”) based on the securities in the Index. The Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, “Genomics & Biotechnology Companies”), as defined by Solactive AG (the “Index Provider”). Genomic and Biotechnology Companies include those involved in the following business activities (i) genomic editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics. In order to be eligible for inclusion in the Index, a company shall generate revenues from relevant activities. (i) Pure-Play which derives at least 50% of revenues from genomics activities which means a process that involves exploring and understanding the structure, function, and evolution of genomes (“Genomics Activities”). (ii) Pre-Revenue which has primary business operations in Genomics Activities but does not currently generate revenues. (iii) Diversified which derives revenues from Genomics Activities but less than 50%. When not possible or practicable to continue to hold all of the component securities of the Index, the Fund may invest in depositary receipts relating either to components securities of the Index or to equity securities of the type referred to above; and financial derivative instruments (“FDIs”), namely, total return “unfunded” OTC swaps and exchange-traded equity futures for investment purposes. The Fund may enter into securities lending transactions, investing in repurchase and reverse repurchase transactions and collective investment schemes, for the purposes of efficient portfolio management only. The Fund’s base currency is USD.
- Leverage100
- Currency hedgingNo